Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Roblox Lawsuit Families are filing Roblox lawsuits after children were targeted by predators for grooming, sextortion, sexual abuse, or exploitation on the platform. Learn who qualifies, what cases allege, and how to file a confidential claim.
Dupixent Lawsuit Dupixent lawsuits are being investigated for patients who developed rare blood cancers such as cutaneous T-cell lymphoma (CTCL) after receiving injections, alleging that Sanofi and Regeneron failed to warn about the potential risks of immune suppression and delayed cancer diagnosis.
Tabletop Fire Pit Lawsuit Individuals who suffered severe burns, or families who lost a loved one in a tabletop fire pit explosion, may be eligible for financial compensation through a fire pit injury lawsuit.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Eisai Never Told Patients in Leqembi Clinical Trials They Faced Higher Risk of Brain Bleeds: NYT Scientists and health experts call the Leqembi clinical trials “ethically fraught,” after drugmaker failed to inform test subjects that they had genetic markers that may make them more susceptible to side effects. October 25, 2024 Martha Garcia Add Your Comments A new investigative report claims that the manufacturer of a new generation Alzheimer’s disease drug failed to disclose safety information needed to allow patients to provide fully informed consent during clinical trials for Leqembi, leading to hundreds of serious side effects and some deaths. According to a New York Times investigative report, drug maker Eisai decided not to tell patients the drug posed a serious risk to some volunteers who had a specific gene, in order to quickly get through the trials and the approval process. As a result, it appears that a number of Leqembi patients suffered severe brain bleeds, brain swelling and some died. The findings were published on Wednesday, as part of an investigation into clinical trials for Alzheimer’s disease drugs introduced by major pharmaceutical companies in recent years. Do You Know about… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Drugs like Leqembi are meant to work by reducing a protein called beta-amyloid that forms plaque in the brains of patients with Alzheimer’s disease. While the drugs do remove the plaques, they are not designed to stop cognitive decline or reverse brain damage. Patients continue to suffer from reduced cognitive function and in many cases, they also suffer from health side effects caused by the drugs themselves. An Australian study in April 2023 warned Leqembi and similar Alzheimer’s drugs like Aduhelm, may even speed up the progression of dementia by causing brain shrinking. Leqembi Clinical Trial Secrecy The New York Times investigation concluded that Eisai recruited volunteers for the Leqembi clinical trial, telling them that they would undergo genetic testing to determine if they carried a specific gene making them prone to developing Alzheimer’s disease. In their recruiting efforts, Eisai reportedly indicated the same gene would also increase the volunteer’s risk of brain bleeds or swelling if they took the drug. However, the investigators say Eisai kept the results of the genetic tests secret and did not tell the patients, a tactic that ethicists say violates informed consent rules. The secrecy provisions were not previously reported during drug trial reviews, or when the drug was approved by the U.S. Food and Drug Administration (FDA) to enter the U.S. market, according to the report. The provision only came to light during the New York Times’ investigation, after journalists reviewed data from clinical trials, patient records, and injury reports, as well as conducted interviews with researchers, neurologists, trial participants, families of Alzheimer’s patients, and FDA officials. Bioethicists said the secrecy provision was “ethically fraught.” More than 100 volunteers who were not given the results of their genetic tests suffered brain bleeding and swelling, the data suggests. Some suffered serious and life-threatening symptoms, and several died. The report indicates one participant took only three doses of the drug and died, after experiencing 51 brain bleeds. An autopsy linked the death directly to side effects of Leqembi. Data from the drug trials also suggested the benefits of Leqembi were modest, the investigation states. Patients experienced a slowing of cognitive decline by a few months, but ultimately the drug did not prevent a complete decline. The lack of more significant results from Leqembi has some researchers thinking the dominant theory of Alzheimer’s being caused by plaque in the brain may be incorrect. Leqembi FDA Approval Despite lackluster clinical trial results, the FDA granted approval of Leqembi for the treatment of Alzheimer’s in 2023, determining the benefits outweighed the risks. In July 2024, the FDA approved another Alzheimer’s drug similar to Leqembi, which also removes plaques from the brain and is marketed under the brand name Kisunla. However, the New York Times report suggests that the manufacturer of that drug, Eli Lily, also failed to disclose the genetic profile and risk to study volunteers in their original clinical study. As a result, the report indicates that dozens of participants experienced what Eli Lily classified as “severe” brain bleeds. In new clinical studies, Eli Lily began giving volunteers the option to learn their test results before entering the Kisunla trial. European Union drug regulators recommended against approving Leqembi in July, and earlier this month Australia declined to approve the drug. Both said the temporary delay of cognitive decline, by five months at most, did not outweigh the risks of Leqembi side effects. FDA Bias Toward Approving New Drugs The FDA has a history of bias toward approving new drugs, according to a study by former FDA advisors. This has become a controversial topic in recent years, particularly involving Alzheimer’s disease treatments. A scientific advisory committee only offers advice on approving or rejecting new drugs. The FDA is not required to follow their recommendations, but the former advisors’ study indicated the agency almost always follows those recommendations when advisors call for a drug’s approval. However, it only follows recommendations for rejecting new drugs about two-thirds of the time. The agency came under fire after it approved the Alzheimer’s disease drug Aduhelm in 2021, when the advisory committee voted against approval. The committee called the approval reckless, since there was no evidence indicating it was beneficial to patients. Two members of the committee resigned in protest of the Aduhelm approval, and a Congressional report indicated the FDA has a close relationship with the drug maker, Biogen. Written by: Martha Garcia Health & Medical Research Writer Martha Garcia is a health and medical research writer at AboutLawsuits.com with over 15 years of experience covering peer-reviewed studies and emerging public health risks. She previously led content strategy at The Blogsmith and contributes original reporting on drug safety, medical research, and health trends impacting consumers. Tags: Alzheimer's Disease, Brain Hemorrhage, Clinical Trials, Eisai, Leqembi More Lawsuit Stories Depo-Provera Brain Tumor Symptoms Create Lifelong Meningioma Fears Among Women September 17, 2025 Bard PowerPort Lawsuit MDL Tops 2,000 Cases September 17, 2025 Investigation into Tesla Door Handle Failures Opened After Children Trapped in Vehicles September 17, 2025 1 Comments Jerry October 27, 2024 My wife has been in the program is remaining in it after the initial 18 months. We were informed of the potential brain swelling and bleeding. It was also in the printed material that we agreed to and signed.. She has also had periodiodical MRI’s over the course of the study. Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermLinkedInThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Depo-Provera Brain Tumor Symptoms Create Lifelong Meningioma Fears Among Women (Posted: today) Women across the U.S. are now pursuing product liability lawsuits and medical monitoring class action claims to secure compensation for potential brain tumor symptoms and side effects linked to the use of Depo-Provera. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (09/03/2025)Pfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025) Safety Problems With Roblox and Discord Endangered Young Girl: Lawsuit (Posted: yesterday) A Texas mother is pursuing a lawsuit against Roblox and Discord, claiming the design of the apps allow sexual predators to access and groom young children. MORE ABOUT: ROBLOX LAWSUITLawsuit Alleges Roblox Lacks Safeguards To Protect Children From Sexual Predators (09/11/2025)Roblox Age Verification Technology To Be Implemented Amid Child Exploitation Lawsuits (09/09/2025)Roblox Kidnapping Lawsuit Filed After Child Was Abducted and Sexually Trafficked (09/03/2025) Dupixent Cutaneous T-Cell Lymphoma Warning Label Update Being Evaluated by FDA (Posted: 2 days ago) Federal regulators are investigating whether Dupixent increases the risk of cutaneous T-cell lymphoma (CTCL), after more than 300 adverse event reports flagged cancer diagnoses among users. The FDA’s review comes as lawsuits are being pursued nationwide, alleging Sanofi and Regeneron failed to warn that the blockbuster eczema drug could either trigger or mask the rare blood cancer. MORE ABOUT: DUPIXENT LAWSUITDupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (09/04/2025)Dupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025)
Investigation into Tesla Door Handle Failures Opened After Children Trapped in Vehicles September 17, 2025
Depo-Provera Brain Tumor Symptoms Create Lifelong Meningioma Fears Among Women (Posted: today) Women across the U.S. are now pursuing product liability lawsuits and medical monitoring class action claims to secure compensation for potential brain tumor symptoms and side effects linked to the use of Depo-Provera. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Meningioma Side Effects Significantly Increased Among Women Over 31: Study (09/03/2025)Pfizer Seeks Dismissal of Depo-Provera Failure-To-Warn Lawsuits Over Meningioma Risks (09/02/2025)Nearly 1,000 Depo-Provera Meningioma Lawsuits Filed, With Another 9,500 Under Investigation (08/25/2025)
Safety Problems With Roblox and Discord Endangered Young Girl: Lawsuit (Posted: yesterday) A Texas mother is pursuing a lawsuit against Roblox and Discord, claiming the design of the apps allow sexual predators to access and groom young children. MORE ABOUT: ROBLOX LAWSUITLawsuit Alleges Roblox Lacks Safeguards To Protect Children From Sexual Predators (09/11/2025)Roblox Age Verification Technology To Be Implemented Amid Child Exploitation Lawsuits (09/09/2025)Roblox Kidnapping Lawsuit Filed After Child Was Abducted and Sexually Trafficked (09/03/2025)
Dupixent Cutaneous T-Cell Lymphoma Warning Label Update Being Evaluated by FDA (Posted: 2 days ago) Federal regulators are investigating whether Dupixent increases the risk of cutaneous T-cell lymphoma (CTCL), after more than 300 adverse event reports flagged cancer diagnoses among users. The FDA’s review comes as lawsuits are being pursued nationwide, alleging Sanofi and Regeneron failed to warn that the blockbuster eczema drug could either trigger or mask the rare blood cancer. MORE ABOUT: DUPIXENT LAWSUITDupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks (09/04/2025)Dupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks (08/26/2025)